Role of glucagon-like peptide-1 in the pathogenesis of experimental irritable bowel syndrome rat models

YAN CHEN*, ZHENGYANG LI*, YAN YANG, LIN LIN and HONGJIE ZHANG

Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China

Received September 2, 2012; Accepted November 1, 2012

DOI: 10.3892/ijmm.2013.1252

Abstract. Alterations in gut motility and visceral hypersensitivity are two major features of irritable bowel syndrome (IBS). The aim of this study was to investigate the roles of glucagon-like peptide-1 (GLP-1) in the pathogenesis of experimental IBS. Rat models of constipation-predominant IBS (IBS-C) and diarrhea-predominant IBS (IBS-D) were established. Fecal water content and behavioral responses to colorectal distension (CRD), using electromyography (EMG), were measured. The expression of glucagon-like peptide-1 receptor (GLP-1R) in the colon was detected by immunohistochemistry, and the serum concentration of GLP-1 was measured by ELISA assay. The movement of circular and longitudinal colonic muscle was detected using an organ bath recording technique. Compared to controls, the fecal water contents were lower in the IBS-C group, while they were higher in the IBS-D group (P<0.05). EMG response to CRD in the experimental IBS groups was increased compared with their respective controls (P<0.05). GLP-1R was localized in the mucosa layer, circular muscle and myenteric nerve plexus of the colon. Notably, the expression of GLP-1R in the IBS-C group was higher, but in the IBS-D group, it was lower compared with controls. The serum levels of GLP-1 in the IBS-C group were higher compared to those in the IBS-D group (P<0.05). In addition, administration of exogenous GLP-1 and exendin-4 inhibited colonic circular muscle contraction, particularly in the IBS-C group, while there was no significant effect on longitudinal muscle contraction. In conclusion, these results indicated that GLP-1 and GLP-1R are implicated in the pathogenesis of IBS-C and IBS-D.

Introduction

Irritable bowel syndrome (IBS) is a chronic, functional gastrointestinal disorder affecting approximately 10-15% of the world’s population. It is characterized by abdominal pain and discomfort and altered bowel habits (1-3). According to bowel habits, IBS is classified into four subgroups: IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), mixed IBS (IBS-M), and untyped IBS (IBS-U) (4,5). Alterations in gut motility and visceral hypersensitivity are two main features of IBS. IBS-associated abdominal pain is believed to result from smooth muscle activity disorder and visceral hypersensitivity (6).

The glucagon-like peptide-1 (GLP-1) analogue ROSE-010 has been found to relieve abdominal pain in patients with IBS (7). GLP-1 is an incretin hormone secreted from L-cells in response to ingested nutrients (8). GLP-1 decreases gastrointestinal motility and gastric emptying in healthy subjects and rodents (9-13). GLP-1 also decreases motility in the antro-duodeno-jejunal region and inhibits the migrating motor complex (MMC) in IBS patients (9). Moreover, GLP-1 exerts inhibitory effects on gastrointestinal motility, not only through vagal afferents and central nervous mechanisms, but also through a peripheral motor action mechanism (14).

The expression of GLP-1 receptors (GLP-1R) has been detected in human small and large intestines (15). In the present study, we aimed to investigate the role of GLP-1 and its receptor in the pathogenesis of experimental IBS rat models by detecting the serum level of GLP-1 and the expression of GLP-1R in the gut. The effect of GLP-1 on circular smooth muscle and longitudinal muscle responses of intestinal segments was also assessed.

Materials and methods

Animals. Fifty adult male Sprague-Dawley rats (200-220 g) were obtained from Beijing Vital River Laboratories Animal Technology Co., Ltd., and were divided into five groups: IBS-C group (n=10); IBS-C control group (n=10); IBS-D group (n=10); IBS-D control group (n=10); and a blank control group (n=10). IBS-C rats were pretreated with 0-4˚C cool water (2 ml) to irrigate the stomach daily for 14 days (16). The IBS-C control rats were treated with normal drinking water (2 ml). IBS-D rats were established by wrap restraint stress as described by Williams et al (17) with slight modifications. The IBS-D control rats were given sham restraint stress.
were given free access to standard rat chow (GB14924.3-2001, China) and water, and they were acclimated for at least 7 days before experiments. The protocol was approved by the Animal Use and Care Committee of Nanjing Medical University.

**Water content of feces.** The rats of each group were placed in separate cages for 3 h, and the amount and weight of the feces expelled by each rat were collected and recorded during this time period. The feces dried in an oven were weighed again. Water content of the feces was calculated by the following formula: Water content % = [wet weight of the feces (g) - dried weight of the feces (g)]/wet weight of the feces (g) x 100% (18).

**Small intestine transit rate.** After fasting for 12 h, each rat received 2 ml of 2% India ink by gavage. Rats were rapidly euthanized and the small intestine samples from the pylorus to the cecum were removed 30 min after receiving India ink. The percentage of small intestine transit was defined as: small intestine transit rate % = the promoting length of the ink (cm)/the total length of intestine (cm) x100% (19).

**Visceromotor response.** Behavioral responses to colorectal distention (CRD) were assessed by a measurement of the electromyogram (EMG) activity of the external oblique (20). Seven days prior to the experiment, stainless steel EMG electrodes were implanted into the lateral abdominal wall of the rats, and the electrode leads were exteriorized at the back of the neck. On the day of the experiment, rats were sedated with isoflurane, and a flexible balloon (5 cm) constructed from a surgical glove finger attached to a catheter was inserted into the descending colon and rectum via the anus; the catheter was fixed to the base of the tail. Rats were placed in small Lucite cubes (20x8x8 cm) (Medical Instrument Co., Ltd., Zhejiang, China). After the rats were fully awake and acclimatized, CRD was performed. Each trial consisted of graded intensity stimulation trials (0, 20, 40 and 60 mmHg) for a 20-sec stimulation period followed by a 2-min rest, and then the procedure was repeated one more time (21). The EMG was recorded continuously during the experiment on an EMG measurement system (Power Labs, Australia). The maximum amplitude of the curve for the EMG signal was calculated.

**Sample preparation.** Blood samples and the colon tissue samples were collected for RNA extraction, western blotting, Colonic muscle strips were made for the smooth muscle contraction experiment. The colon tissue sections were used for hematoxylin and eosin (H&E) staining, immunohistochemistry. H&E-stained sections were scored for colonic inflammation in model rats as previously described (22).

**GLP-1R immunohistochemistry.** The sections were incubated with anti-GLP-1R antibody (AB-39072; Abcam) at a final dilution of 1:100 for 24 h at 4˚C. The immunoreaction was revealed by using horseradish peroxidase (HRP)-labeled secondary mouse anti-rabbit antibody (1:500; Jingmei Biological Engineering Co., Ltd., Shenzhen, China) for 2 h at room temperature. The slides were mounted and scanned using a microscope (Olympus, Tokyo, Japan). Five high power fields (x400) from each slide were randomly selected for analysis using Image-Pro Plus image analysis software. The average optical density value represents the relative expression of proteins.

**Quantitative real-time PCR.** GLP-1R gene expression in the colon was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR). Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA). One microgram of total RNA was reverse-transcribed in a final volume of 50 µl using the ABI PRISM cDNA Archive kit. β-actin and GLP-1R were amplified using 5 µl of cDNA per reaction. The primers and TaqMan fluorogenic probes were purchased from Invitrogen. β-actin was used as an internal gene. The primers for rat GLP-1R and β-actin were as follows: GLP-1R, forward, 5'-CA TCGTGGTATCCAAACTGA-3' and reverse, 5'-GCTCGTGGCT ATACAAAGG-3'; β-actin, forward, 5'-TATGACCTTAGTTG CGTTACACC-3' and reverse, 5'-CCTTCACCGTTCCAGTTT TT-3'. The amplification reaction was performed in an ABI PRISM 7500 fluorescence quantitative PCR instrument using the following conditions: 50˚C for 2 min, 95˚C for 10 min and 95˚C for 15 sec, and a final extension step of 1 min at 66˚C, 40 cycles, stored at 4˚C. The data were analyzed by the relative gene expression, which was determined using the 2^-ΔΔCt method (23).

**Western blotting.** A colon tissue sample (100 mg) was homogenized in a buffer containing 25 mM Tris-HCl (pH 7.5), 5 mM EDTA, 5 mM EGTA, 0.5 mM PMSF, 25 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 mM sodium vanadate. The crude protein homogenates with sample buffer were boiled for 5 min. Samples were subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (10 mg/lane) and then transferred to a polyvinylidene difluoride membrane for immunoblotting. The membranes were incubated in blocking buffer (5% non-fat milk in Tween/Tris-buffered salt solution, TTBS) containing anti-GLP-1R antibody (1:400; Abcam Ltd.). Following multiple washes, the membranes were incubated for 1.5 h at room temperature with secondary antibody (1:1,000) linked to horseradish peroxidase (HRP). The immunopositive proteins on the membrane were detected by an enhanced chemiluminescence detection kit (ECL; Millipore, Bedford, MA, USA). The target band and the band for β-actin were quantified by the ‘Tianmeng GIS gel image processing system for optical density analysis.

**Detection of serum GLP-1 levels by ELISA.** The blood samples were collected and DPP-4 inhibitor (Millipore) was added to the blood samples. Following centrifugation at 4,000 x g for 10 min at 4˚C, the supernatants were stored at -20˚C until detection. The serum level of GLP-1 (7-36) was measured by ELISA (Linco Research Inc.). An aliquot of 100 µl of each sample was added to each assay well. ELISA has a working range of 2-100 pM.

**Validation of the effects of GLP-1 and its receptor agonists on rat colon circular and longitudinal muscle strips in rat models of IBS-C and IBS-D.** The muscle strips were obtained by cutting along the longitudinal axis of the colon were the longitudinal muscle strips (2x10 mm), and along the circular axis were the circular muscle strips (2x10 mm), as previously reported (24). The muscle strips were suspended in a designed horizontal organ bath, which contained 10 ml of Krebs solution, continu-
ously perfused with a 95% O₂ and 5% CO₂ mixture, and heated (37°C) in Krebs solution with the following composition: 119 mM NaCl, 4.5 mM KCl, 2.5 mM MgSO₄, 25 mM NaHCO₃, 1.2 mM KH₂PO₄, 2.5 mM CaCl₂, and 11.1 mM glucose, pH 7.4. One end of each strip was fixed to organ holders, and the other end was fastened by a silk tie to an isometric tension transducer (National Institute for Physiology, Japan). Each muscle strip was slowly stretched at an initial tension of 0.5 g and allowed to equilibrate for 60 min to reach a steady baseline before experiments. Then, saline, GLP-1, and exendin-4 were added, respectively, and the effects of these peptides on the IBS subtypes and matched controls were evaluated. After the addition of GLP-1 and exendin-4, respectively, the contraction curve was recorded within 5 min. The peptides were then eluted in the bath, and the next trial was not performed until the smooth muscle strips were restored to a steady state. We took the area under the curve (AUC) of saline as 100%: data were expressed as the percentage of the AUC obtained in the presence of saline on the ACh pretreated muscle strips. Mechanical signals from each strip were amplified with an amplifier, recorded, and analyzed using Med Lab 6.0 software (MedEase, Nanjing, China).

Statistical analysis. Data are presented as the means ± SD. Analyses were performed using SPSS 13.0 software (Jandel Scientific-SPSS Science, Chicago, IL, USA). The IBS subtypes and control groups were compared, and data were analyzed using one-way ANOVA followed by Bonferroni post-test comparisons. P<0.05 was considered to indicate statistically significant differences.

Results

Feces changes in experimental IBS-C and IBS-D rat models. To validate the successful establishment of rat models of IBS-C and IBS-D, water content of the feces and feces weight in the experimental IBS models were measured. The fecal pellets in
the IBS-C group weighed less than those in the control group (P<0.05); the fecal pellets in the IBS-D group weighed more than those in the control group (P<0.05) (Fig. 1). In addition, the water content of the feces in the IBS-C rats was significantly less, and water content in the feces of IBS-D rats was significantly more compared with the control rats (P<0.05) (Fig. 1). These results suggested that the models of IBS-C and IBS-D were established successfully.

**Visceromotor responses in experimental IBS rat models.** A significant increase in the maximum amplitude curve of the EMG in response to increased CRD pressure in both experimental IBS rats was detected (Fig. 2). The mean amplitudes in both IBS-C and IBS-D rats exhibited higher responses to different distention pressures compared with their matched controls, respectively. These data indicated that the IBS model groups were more sensitive to CRD compared with controls, suggesting that gastric instillation of cool saline and wrap restraint stress produced a persistent visceral hypersensitivity in IBS-C and IBS-D rats.

**Figure 3.** Changes of small intestine transit rate in experimental IBS-C and IBS-D. The small intestine transit rate for the experimental IBS-C group was slower than its matched control groups. However, for the experimental IBS-D group, it was faster than its matched control groups. Small intestine transit rate % = the promoting length of the ink (cm)/the total length of intestine (cm) x100%. IBS-C group, constipation-predominant experimental IBS group; IBS-D group, diarrhea-predominant experimental IBS group.

**Figure 4.** Immunohistochemical assessment of GLP-1R expression in experimental IBS-C and IBS-D. (A) GLP-1R immunoreactivity was observed in the colon mucosa layer and circular muscle and myenteric plexus of all samples (arrows). (B) GLP-1R in the experimental IBS-C group was higher than that in its control groups and the IBS-D group (P<0.01 vs. the IBS-C control and the blank control group). On the contrary, GLP-1R immunoreactivity in the IBS-D group was significantly lower than that in the control groups (P<0.01 vs. the IBS-D control and the blank control group). IBS-C group, constipation-predominant experimental IBS group; IBS-D group, diarrhea-predominant experimental IBS group.
Small intestine transit rate in experimental IBS rat models.
To observe the motility changes in experimental IBS-C and IBS-D \textit{in vivo}, we measured the small intestine transit rate. As shown in Fig. 3, the small intestine transit rate in IBS-C rats was lower than that in IBS-D controls and blank controls (51.17±2.32 vs. 62.09±2.22, P<0.05 and 62.60±1.89, P<0.05, respectively). In IBS-D rats, the small intestine transit rate was higher compared with that in IBS-D controls and blank controls (70.69±2.91 vs. 62.39±2.31, P<0.05 and 62.60±1.89, P<0.05, respectively). These results suggested that small intestine transit in IBS-D rats was accelerated, while the small intestine transit in IBS-C was delayed, compared with their controls, respectively.

Expression of GLP-1R in the colon. To study the GLP-1 signaling implication in IBS, we investigated the expression changes of GLP-1R in experimental IBS-C and IBS-D.

Expression of GLP-1R mRNA and protein in experimental IBS-C and IBS-D colons. (A) Expression of GLP-1R transcript levels was significantly higher in the colon from experimental IBS-C rats compared with control groups (P<0.01) and the experimental IBS-D group (P<0.01). (B) Representative western blot analyses for GLP-1R (upper panel) and β-actin (lower panel) for rat colon from experimental IBS subtypes in comparison with control; the GLP-1R protein level was also higher in the experimental IBS-C group, compared with the control and experimental IBS-D group (P<0.01), IBS-C group, constipation-predominant experimental IBS group; IBS-D group, diarrhea-predominant experimental IBS group.

Circulating GLP-1 levels. The average serum level of GLP-1 in the IBS-C group was significantly higher than that in the IBS-D group (10.76±3.1 vs. 6.37±1.93 pM, P<0.05). However, no significant difference of serum GLP-1 level was detected between these two IBS subtype models and control group (P>0.05) (Fig. 6). These results suggested that GLP-1 may be involved in IBS subtype formation.

Effects of GLP-1 and its receptor agonists on colon muscle strips in experimental IBS rat models. To determine the involvement of GLP-1 in the pathogenesis of IBS, we tested the responses of colon muscle strips to GLP-1 and exendin-4. Following pretreatment of muscle strips with ACh, the optimal concentration of GLP-1 (1.0x10^{-7} M) or exendin-4 (8.0x10^{-8} M) was added. We found that GLP-1 and exendin-4 had no effect on Ach-pretreated longitudinal muscle strips (Fig. 7B), while
they exerted inhibitory effects on Ach-pretreated circular muscle strips in both experimental IBS models and control groups (Fig. 7A). Furthermore, the inhibition by GLP-1 or exendin-4 on Ach-pretreated circular muscle strips in the IBS-C group was more obvious compared to that in the IBS-D group (P<0.05) (Fig. 7C and D).

Discussion

In recent years, several different animal models of IBS have been established to investigate the pathogenesis and treatment of IBS. However, so far there has not been a perfect model imitating the clinical manifestations of IBS patients. In our study, the IBS-C group was established by gastric instillation of 0-4°C saline daily for 14 days (16), and the IBS-D group was established by wrap restraint stress (17). The IBS-D rats showed visceral hypersensitivity and defecated more stool compared with the control rats, which was in accordance with the clinical observations in IBS-D patients. Regarding the IBS-C model, no marked inflammation was found in the colon after gastric instillation with 0-4°C cool water daily for 14 days. Compared with the blank control, the amount, weight, and water content of the feces expelled by the IBS-C rats were significantly less, and the time before the first black stool occurred in the IBS-C group was significantly longer than that in the control groups.

Previous studies found that GLP-1 can slow gastric emptying and inhibit intestinal movement (25-27). A clinical case report (28) indicated that a patient with a neuroendocrine tumor who had high serum levels of GLP-1 (300 to 400-fold) had markedly delayed gastrointestinal transit and severe intractable constipation. Normal bowel function was restored after tumor resection. This indicates that GLP-1 is involved in the formation of constipation, but the underlying mechanism remains unclear. Our observations showed that the serum bioac-
tive GLP-1 level in the IBS-C group was higher compared with the control group, which indicates that an increased bioactive GLP-1 level may be related to the formation of constipation in experimental rats. In addition, our results showed that exogenous GLP-1 and its receptor agonist, exendin-4, can effectively inhibit colon circular muscle contraction in a rat experimental IBS model, while having no effect on longitudinal muscle contraction. These results can be explained by the fact that GLP-1R was located in the circular muscle and myenteric neurons, while no GLP-1R-positive staining was detected in the longitudinal muscle. These results are consistent with the report of Amato et al. (14), who showed that GLP-1R was detected in some myenteric neurons in rats, and GLP-1 regulated the release of NO to decrease the excitatory cholinergic neurotransmission by acting on the presynaptic GLP-1R, and then inhibited the intestinal movement.

As circular muscle contraction is dominant in peristalsis, the action of GLP-1 could contribute to the reduction of intestinal transit (14). In our study, GLP-1 and its receptor agonist inhibited rat colonic circular muscle, particularly in the IBS-C group, suggesting that the high serum levels of GLP-1 and high expression of GLP-1R in the IBS-C group inhibited colonic movement to cause the dry stool and sluggish rat small intestine transit, leading to constipation. In summary, GLP-1 and its receptors may be involved in altered gastrointestinal motility in the pathogenesis of IBS.

The gastrointestinal mucosa may receive a variety of stimuli to impart various types of signals to the central nervous system and lead to sensory dysregulation. Our results showed that GLP-1R is mainly expressed in the colon mucous layer, and its expression varied among the experimental IBS subtypes, indicating that GLP-1 and GLP-1R might be related to the formation of visceral hypersensitivity in IBS models; however, this requires further investigation.

In conclusion, our results showed that GLP-1 and GLP-1R altered gastrointestinal motility of experimental IBS-C and IBS-D, suggesting a potentially important role for GLP-1 and GLP-1R in IBS-C and IBS-D and motility dysfunction.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (no. 30771039) and the Key Medical Personnel of Jiangsu Province (no. RC2011063)

References